Pharmaceutical News

RSS

WHO using new bivalent oral polio vaccine in Afghanistan

The WHO on Tuesday launched a vaccination campaign in Afghanistan that will use "a new and more effective polio vaccine" for the first time, Reuters reports (Nebehay, 12/15).

16 Dec 2009

Syntiron grants sanofi pasteur exclusive world-wide license to its human vaccine against MRSA

Syntiron today announced that it has granted sanofi pasteur an exclusive world-wide license to its human vaccine against Staphylococcus aureus. The agreement includes an undisclosed initial licensing fee, milestone payments and royalty payments on future sales of the product. Staphylococcus aureus, or MRSA (pronounced Mer-sa) is an important hospital-acquired infection and is a major cause of illness and death resulting in excess of 18,000 US deaths a year and a half million hospitalizations, creating a significant economic burden of approximately $3.4 billion annually to the American health care system.

16 Dec 2009

NanoBio, GSK partner to develop and commercialize novel cold sore treatment compound

GlaxoSmithKline plc and NanoBio Corporation today announced an exclusive licensing agreement in the United States and Canada for the over-the-counter (OTC) use of NB-001, a novel, patented compound representing the next advance in the treatment of cold sores. Developed by NanoBio, NB-001 provides significant antimicrobial activity against the virus that causes cold sores, herpes labialis.

16 Dec 2009

Amendment to allow drug importation fails in Senate

A bipartisan plan to allow Americans to buy cheaper prescription drugs from suppliers in other countries, such as Canada, failed Tuesday in the Senate. The Wall Street Journal reports the two top supporters of the plan, Sens. Byron Dorgan, D-N.D., and John McCain, R-Ariz., said shopping overseas via the Internet and mail-order companies could save consumers up to $80 billion over a decade if their amendment were added to the health overhaul legislation.

16 Dec 2009

Walgreens offers H1N1 vaccine in 27 states

Walgreens, the nation’s largest drugstore chain and an industry leader with more than 17,000 certified or licensed immunizers, today announced it is offering H1N1 vaccine at more than 1,500 Walgreens pharmacies and select Take Care Clinics in 27 states, as well as the District of Columbia.

16 Dec 2009

EU border security market boosted by unauthorised immigration and illegal drug trafficking

European Union (EU) member states are spending more on protecting their borders, which are increasingly subjected to unauthorised immigration and illegal drug trafficking. High investment in advanced technology security and IT-based systems will boost the border security market.

16 Dec 2009

Pharmacy directors willing to cover tanezumab at lower prices

HealthLeaders-InterStudy and Fingertip Formulary find that 70 percent of surveyed pharmacy directors expect to cover Pfizer's tanezumab if it is approved for the treatment of chronic pain. Tanezumab, which is expected to be the first biologic approved for chronic pain and is administered intravenously under medical supervision, will likely be covered as a medical benefit rather than a pharmacy benefit according to surveyed pharmacy directors.

16 Dec 2009

Almac Diagnostics expands its Bioinformatics department

Almac has shown significant growth in the last year, with employee numbers growing by 15% in the UK and 10% in the US. For the Diagnostics division, this trend continues through the expansion of the Bioinformatics Department and the subsequent opening of a dedicated bioinformatics facility in Manchester (UK).

16 Dec 2009

Avastin may lose significant patient share to Sanofi-Aventis' BSI-201, according to report

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that an overall survival benefit would be the most influential factor for three-quarters of surveyed European oncologists in their decision to prescribe a novel agent ahead of Avastin for the treatment of breast cancer.

16 Dec 2009

MRSA, the most concerning pathogen to surveyed for skin and skin structure infections

Arlington Medical Resources (AMR) and Decision Resources find that methicillin-resistant Staphylococcus aureus (MRSA) is the most concerning pathogen to surveyed European infectious disease specialists with regard to their treatment of skin and skin structure infections.

16 Dec 2009

Pharmaceutical manufacturers controlling health reform debate, Senate disallows prescription drug import

The failure of the U.S. Senate to allow importation of prescription drugs to cut costs, much less the more effective direct bulk purchasing of prescription drugs, is just the latest example of how big industry controls the health reform debate, according to Consumer Watchdog.

16 Dec 2009

Thomson Reuters offers integrated clinical trial protocol and outcome information for customers

Thomson Reuters today announced that Thomson Pharma® has become the first drug pipeline database to fully integrate detailed clinical trial protocol and outcome information. This highly anticipated new content is being provided to all Thomson Pharma customers this month.

16 Dec 2009

Englerin A possesses high toxicity for kidney cancer cells, researchers discover

Englerin A, a natural product recently discovered in an African plant, possesses high toxicity for kidney cancer cells but low toxicity for other cells. Therefore this compound is potentially qualified for further evaluation toward an application in cancer therapy.

16 Dec 2009

Preclinical study of Arno Therapeutics' drug candidate AR-42 presented at ASH 2009

Arno Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on oncology therapeutics, today announced the presentation of a poster at the annual American Society of Hematology (ASH) meeting that describes the preclinical activity of Arno’s drug candidate AR-42 against leukemia stem cells (LSCs).

16 Dec 2009

AstraZeneca's CRESTOR receives favorable vote from FDA Advisory Committee

The U.S. Food and Drug Administration (FDA) Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) today voted 12 yes, 4 no, and 1 abstention that AstraZeneca has established sufficient benefit to offset the observed risks to support the use of CRESTOR®

16 Dec 2009

New top-line results for patient preference study evaluating Kristalose for Oral Solution announced

Cumberland Pharmaceuticals Inc. (CPIX) today announced new top-line results for a patient preference study evaluating Kristalose (lactulose) for Oral Solution, a prescription laxative packaged as a crystalline powder, compared to similar products in liquid forms.

16 Dec 2009

Rib-X Pharmaceuticals and MGH enter into collaborative research agreement

Rib-X Pharmaceuticals, Inc., a company focused on the discovery, development and commercialization of novel drugs for the treatment of serious multi-drug-resistant infections announced today it has entered into a collaborative research agreement with Massachusetts General Hospital (MGH).

16 Dec 2009

Researchers develop new electrophoretic method for detecting MIRCERA and EPO in blood

Austrian researchers have successfully developed a new electrophoretic method for detecting MIRCERA® and other erythropoietins (EPO) in the blood. The technique, using SARCOSYL-PAGE, has specifically enhanced sensitivity for MIRCERA, but does not alter the performance characteristics of SDS-PAGE for detecting other EPOs.

16 Dec 2009

InSite Vision to advance new development candidate ISV-303

InSite Vision Incorporated, a company developing ophthalmic products for unmet eye care needs, today announced plans to advance new development candidate ISV-303, a topical anti-inflammatory product intended to reduce the pain and swelling associated with ocular surgery.

16 Dec 2009

FDA grants approval to market InterSol platelet additive solution

Fenwal Inc., a global medical technology company focused on improving blood collection, separation, safety and availability, announced today that the U.S. Food and Drug Administration has granted Fenwal approval to market InterSol® platelet additive solution.

15 Dec 2009

Pharmaceutical News

WHO using new bivalent oral polio vaccine in Afghanistan

Syntiron grants sanofi pasteur exclusive world-wide license to its human vaccine against MRSA

NanoBio, GSK partner to develop and commercialize novel cold sore treatment compound

Amendment to allow drug importation fails in Senate

Walgreens offers H1N1 vaccine in 27 states

EU border security market boosted by unauthorised immigration and illegal drug trafficking

Pharmacy directors willing to cover tanezumab at lower prices

Almac Diagnostics expands its Bioinformatics department

Avastin may lose significant patient share to Sanofi-Aventis' BSI-201, according to report

MRSA, the most concerning pathogen to surveyed for skin and skin structure infections

Pharmaceutical manufacturers controlling health reform debate, Senate disallows prescription drug import

Thomson Reuters offers integrated clinical trial protocol and outcome information for customers

Englerin A possesses high toxicity for kidney cancer cells, researchers discover

Preclinical study of Arno Therapeutics' drug candidate AR-42 presented at ASH 2009

AstraZeneca's CRESTOR receives favorable vote from FDA Advisory Committee

New top-line results for patient preference study evaluating Kristalose for Oral Solution announced

Rib-X Pharmaceuticals and MGH enter into collaborative research agreement

Researchers develop new electrophoretic method for detecting MIRCERA and EPO in blood

InSite Vision to advance new development candidate ISV-303

FDA grants approval to market InterSol platelet additive solution

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News